Cyxone enters into co-operation agreement with University of Queensland
Cyxone AB and the University of Queensland in Australia are launching a co- operation agreement to continue studies into the effects of Cyxone's T20K development substance in combating MS.Cyxone has signed an agreement with the University of Queensland to study how "therapeutic dosing" with T20K can inhibit the development of fresh MS symptoms in treated animals. The programme will seek to identify the conditions for early treatment with T20K in humans, and is included in the documentation that forms the basis for further studies in humans. The co-operation agreement covers several